Babson Diagnostics partnered with Orchard Software in 2019 to support the research and development phase of their innovative blood collection, processing, and testing methodology. With extensive research studies backing their invention, the company launched BetterWay™ blood testing and transitioned into a commercial laboratory in 2024, leveraging Orchard’s products for connectivity and efficiency.
Babson Launches FDA-approved Fingerstick Device
Babson launched their startup company in 2017, in Austin, Texas. Babson worked with Becton Dickinson to develop a capillary blood collection device—the FDA-cleared BD MiniDraw™ Capillary Blood Collection System—that uses about one tenth of the amount of blood typically collected in a venous draw. Samples drawn at pharmacies are tested at the BetterWay clinical laboratory using traditional laboratory analyzers. The test menu offers chemistry, immunoassay, and hematology.
Transition from Harvest LIS to Enterprise Lab
Babson implemented Orchard® Harvest™ in 2019 as a research and development lab. The Orchard solution was easy to deploy and easy to use, making it an excellent choice for their clinical trial-level testing volumes.
As they transitioned from being a research laboratory to a commercial laboratory, they needed to invest in an enterprise-level laboratory information system (LIS). After a thorough search, Babson selected Orchard® Enterprise Lab™ for its superior scalability, flexibility, and user experience.
Heath Marr, Director of Laboratory Operations at Babson Diagnostics, said, “We provide a high level of performance and customer service thanks to the smooth and efficient lab workflows enabled by the Orchard Enterprise Lab LIS.”
Read the full Babson Diagnostics customer testimonial article.
Read the Babson Diagnostics Press Release.